Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MANNKIND CORP

Get SEC filing alerts via email and in your feed for MANNKIND CORP

MNKD

MANNKIND CORP

About MANNKIND CORP

MannKind Corporation is a biopharmaceutical company specializing in developing and commercializing innovative inhalation-based therapies for endocrine and orphan lung diseases. Its core products include Afrezza, an inhaled insulin, and V-Go, a wearable insulin delivery device. The company leverages proprietary Technosphere dry-powder formulations and inhaler technologies to deliver rapid, convenient treatments primarily in the U.S. and select international markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from MANNKIND CORP

1
1
MANNKIND CORP MannKind Corporation Reports $90.2 Million Revenue in Q1 2026, Net Loss of $16.6 Million

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MANNKIND CORP MannKind Corporation Reports 22% Revenue Growth to $348.97 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
MANNKIND CORP MannKind Corporation Reports 17% Revenue Growth to $82.1 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MANNKIND CORP MannKind Corporation Reports 6% Revenue Growth to $76.5 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MANNKIND CORP MannKind Corporation Reports 18% Revenue Growth to $78.4 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MANNKIND CORP MannKind Corporation Reports 43% Revenue Increase to $285.5 Million for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
MANNKIND CORP MannKind Corporation Reports 37% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments